The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients

Biological Trace Element Research

Volumn 56, Issue 3, 1997, Pages 331-341

  Hu, Ya Jun ^a   Chen, Yan ^a   Zhang, Yong Qiang ^a   Zhou, Mei Zhen ^a   Song, Xue Mei ^b   Zhang, Bao Zhu ^a   Luo, Ling ^a   Xu, Pei Min ^a   Zhao, Yi Niam ^a   Zhao, Yun Bo ^a   Cheng, Gang ^a  

^a BEIJING HOSPITAL   (China)

^b Beijing TianXinFu Medical Appliance Co   (China)

Author keywords

Cancer patients; Cisplatin; Selenium (Seleno Kappacarrageenan); Toxicity (nephrotoxicity, bone marrow suppression)

Indexed keywords

CARRAGEENAN; CISPLATIN; SELENIUM DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION;

EID: 8244221011     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02785304     Document Type: Article

References (33)

1. A. W. Prestayko, S. T. Crooke, and S. K. Carter, eds. Cis-platin: Current Status and New Developments. Academic, New York (1980).
2. T. P. Luckey and B. Wenugopol, Metal Toxicity in Mammals, vol. 2. Elsevier/North-Holland, Amsterdam (1977).
3. I. H. Krakoff, Nephrotoxicity of cis-dichlorodiammineplatinum (II), Cancer Treat. Rep. 63, 1523-1525 (1979).
4. E. M. Walker and G. R. Gale, Methods of reduction of cis-platin nephrotoxicity, Ann. Clin. Lab. Sci. 11, 397-410 (1981).
5. W. C. Rose and J. E. Schurig, Preclinical antitumor and toxicological profile of carboplatin, Cancer. Treat. Rep. 12(suppl. A), 1-9 (1985).
6. R. F. Ozols, B. J. Cordon, J. Jacob, M. N. Wesley, Y. Ostehega, and R. C. Young, High-dose cis-platin in hypertonic saline, Ann. Inter. Med. 100, 19-24 (1984).
7. C. E. Pfeifle, S. B. Howell, R. D. Felthouse, T. B. Woliver, P. A. Andrews, M. Markman, and M. P. Murphy, High dose-cis-platin with sodium thiosulfate protection, J. Clin. Oncol. 3, 237-244 (1987).
8. D. L. Bodenner, P. C. Dedon, J. C. Katz, and R. F. Borch, Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate, Cancer. Res. 46, 2751-2755 (1986).
9. M. L. Rothenberg, Y. Ostchega, S. M. Steinberg, R. C. Young, S. Hummel, and R. F. Ozols, High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer, J. Natl. Cancer Inst. 80, 1488-1492 (1988).
10. M. Satoh, A. Naganuma, N. Imura. Deficiency of selenium intake enhances manifestation of renal toxicity of cis-diamminedichloroplatinum in mice, Toxicol. Lett. 38(1-2), 155-160 (1987).
11. L. N. Vernie, J. J. de-Goeij, C. Zeger, M. Devries, G. S. Baldew, and J. G. Mevie. Cis-platin-induced changes of selenium levels and glutathione peroxidase activities in blood of testis tumor patients, Cancer. lett 40(1), 83-91 (1988).
12. V. R. Young, Selenium: a case for its essentiality in man, N. Engl. J. Med. 304, 1228 (1981).
13. R. J. Shamberger and D. V. Frost, Possible protective effect of selenium against human cancer, Can. Med. Ass. J. 103, 682 (1969).
14. Y. J. Chu, Q. Y. Liu, C. Hou, and S. Y. Yu, Blood selenium concentration in residents of areas in China having a high incidence of lung cancer, Biol Trace Element Res. 6(2), 133-137 (1984).
15. W. Willett, B. F. Polk, S. Morris, M. J. Stampfer, S. Pressel, B. Rosnern, J. O. Taylor, K. Schneider, and C. G. Hames, Prediagnostic serum selenium and risk of cancer, Lancet 2, 130-134 (1983).
16. P. Knekt, A. Aromaa, L. Maateta, et al. Serum selenium and subsequent risk of cancer among Finnish men and woman, J. Nat. Cancer Inst. 82(10), 846-848 (1990).
17. K. P. McConnell, W. L. Broghamer, A. J. Blotcky, Selenium levels in human blood and tissue in health and disease, J. Nutr. 105, 1026-1031 (1975).
18. Y. J. Hu, Y. N. Zhao, P. M. Xu, S. D. Yang, Y. W. Lin, and J. H. Wu, A study of blood selenium levels in patients with lung cancer and healthy subjects in Beijing area, Acta Nutrimenta. Sinica. 16(3), 261-264 (1994).
19. C. Ip. Factors influencing the anticarcinogenic efficacy of selenium in dimethylbenz (a)anthracene-induced mammary tumorigenesis in rats, Cancer Res. 41, 2683-2686 (1981).
20. C. Ip, M. M. Ip, and U. Kim, Dietary selenium intake and growth of MT-W9B transplantable rat mammary tumor, Cancer Lett. 14, 101-107 (1981).
21. G. Hocman, Chemoprevention of cancer: selenium, Int. J. Biochem. 20(2), 123-132 (1988).
22. A. M. Watrach, J. A. Milner, M. A. Watrach, and K. A. Poirier, Inhibition of human breast cancer cells by selenium, Cancer Lett 25(1), 41-47 (1984).
23. S. Y. Yu, Y. J. Chu, W. G. Li, Q. S. Huang, C. Z. Huang, Q. N. Zhang, and C. Hou, A preliminary report on the intervention trials of primary liver cancer in high risk populations with nutritional supplementation of selenium in China. Biol. Trace Elements Res. 29, 289-294 (1991).
24. W. L. Blot, J. Y. Li, P. R. Taylor, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population, J. Natl. Cancer. Inst. 85(18), 1483-1492 (1993).
25. A. Naganuma, M. Satoh, M. Yokoyama, and N. Imura, Selenium efficiently depressed toxic side effect of cis-diamminedichloroplatinum, Res. Commun. Chem. Pathol. Pharmacol. 42(1), 127-134 (1983).
26. J. P. Berry, C. Pauwells, S. Tlouzeau, and G. Lespinats, Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma, Cancer. Res. 44(7), 2864-2868 (1984).
27. M. Yokoyama, A. Naganuma and N. Imura, Suppression of CDDP-induced renal toxicity by sodium selenite. Gan. No. Rinsho. (Japanese) 31(9 Suppl), 1225-1230 (1985).
28. K. Ohkawa, Y. Tsukada, and H. Dohzono, K. Koike, and Y. Terashima, The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity, Br. J. Cancer. 58(10), 38-11 (1988).
29. G. S. Baldew, C. J. Van-den Hamer, G. Los, N. P. E. Vermeulen, J. J. M. de Goeij, and J. G. Mevie, Selenium-induced protection against cis-diamminedichloroplatinum (II) nephrotoxicity in mice and rats, Cancer. Res. 49(11), 3020-3023 (1989).
30. G. S. Baldew, J. G. McVie, M. A. Van-der-valk, G. Los, J. J. de Goeij, and N. P. E. Vermeulen, Selective reduction of cis-diammindichloroplatinum(II) nephrotoxicity by ebselen. Cancer. Res. 50(21), 7031-7036 (1990).
31. Y. Araya, Studies on protective effect of selenium on the nephrotoxicity of cis-diamminedichloroplatinum(CDDP) in mice, Hokkaido. Igoaku. Zasshi. 65(3), 245-253 (1990).
32. M. Satoh, A. Naganuma, and N. Imura, Optimum schedule of selenium administration to reduce lethal and renal toxicities of cis-diamminedichloroplatinum(cis-DDP) in mice, J. Pharmacobiodyn. 12(4), 246-253 (1989).
33. B. Leyland Jones, C. Morrow, S. Tate, C. Urmacher, C. Gordon, and C. W. Young, Cis-diamminedichloroplatinum(II) nephrotoxicity and Its relationship to renal to gamma-glutamyl transpeptidase and glutathione, Cancer. Res, 43(12 pt 1), 6072-6076 (1983).